( March 17, 2025, 3:31 PM EDT) -- WASHINGTON, D.C. — High court review is needed again in the long-running Fosamax femur fracture multidistrict litigation, the drug manufacturer says in a petition for certiorari, arguing that the Third Circuit U.S. Court of Appeals “defied” a 2019 U.S. Supreme Court ruling, “gutting drug preemption and rendering itself an outlier among the Circuits” when it found that state law claims are not preempted and reversed the decision that awarded the drug manufacturer summary judgment in 1,046 cases....